EP1128839A4 - Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd - Google Patents

Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd

Info

Publication number
EP1128839A4
EP1128839A4 EP99960378A EP99960378A EP1128839A4 EP 1128839 A4 EP1128839 A4 EP 1128839A4 EP 99960378 A EP99960378 A EP 99960378A EP 99960378 A EP99960378 A EP 99960378A EP 1128839 A4 EP1128839 A4 EP 1128839A4
Authority
EP
European Patent Office
Prior art keywords
hvgd
preventing
methods
pharmaceutical compositions
synthetic peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99960378A
Other languages
German (de)
French (fr)
Other versions
EP1128839A1 (en
Inventor
Rina Aharoni
Dvora Teitelbaum
Ruth Arnon
Michael Sela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of EP1128839A1 publication Critical patent/EP1128839A1/en
Publication of EP1128839A4 publication Critical patent/EP1128839A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
EP99960378A 1998-11-12 1999-11-12 Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd Withdrawn EP1128839A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10818498P 1998-11-12 1998-11-12
US108184P 1998-11-12
US14521999P 1999-07-23 1999-07-23
US145219P 1999-07-23
PCT/US1999/027107 WO2000027417A1 (en) 1998-11-12 1999-11-12 Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd

Publications (2)

Publication Number Publication Date
EP1128839A1 EP1128839A1 (en) 2001-09-05
EP1128839A4 true EP1128839A4 (en) 2002-10-09

Family

ID=26805609

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99960378A Withdrawn EP1128839A4 (en) 1998-11-12 1999-11-12 Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd

Country Status (4)

Country Link
EP (1) EP1128839A4 (en)
AU (1) AU775073C (en)
CA (1) CA2355400A1 (en)
WO (1) WO2000027417A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005250A1 (en) 1998-07-23 2000-02-03 Yeda Research And Development Co., Ltd Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
ES2527760T3 (en) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Treatment of Crohn's disease with copolymer 1 and polypeptides
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
ZA200206457B (en) 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
ATE475883T1 (en) 2001-12-04 2010-08-15 Teva Pharma METHOD FOR MEASURING THE POWER OF GLATIRAMER ACETATE
PT1592384E (en) * 2003-01-21 2013-01-28 Yeda Res & Dev Cop 1 for treatment of inflammatory bowel diseases
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
EP1750741B1 (en) 2004-05-07 2015-12-02 Ares Trading S.A. Methods of treating disease with random copolymers
SI2177528T1 (en) 2004-09-09 2012-04-30 Teva Pharma Process for the preparation of mixtures of trifluoroacetyl glatiramer acetate using purified hydrobromic acid
US7560100B2 (en) 2004-09-09 2009-07-14 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases
ES2331015T3 (en) 2004-10-29 2009-12-18 Sandoz Ag PROCESS FOR THE PREPARATION OF A GLATIRAMERO.
EP1843802A2 (en) * 2005-01-31 2007-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Polyelectrolyte multilayer film, preparation and uses thereof
CA2649296A1 (en) 2006-04-13 2007-10-25 Peptimmune, Inc. Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
US9533037B2 (en) 2007-10-16 2017-01-03 Declion Holdings Llc Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
EP3199172B1 (en) 2009-08-20 2018-07-11 Yeda Research and Development Co., Ltd. Dosing regimen for multiple sclerosis
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
ES2699692T3 (en) 2010-01-04 2019-02-12 Mapi Pharma Ltd Deposit system comprising glatiramer acetate
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
ES2602977T3 (en) 2010-10-11 2017-02-23 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as biomarkers predictive of the clinical response for glatiramer acetate
WO2012143924A1 (en) 2011-04-21 2012-10-26 Mapi Pharma Ltd. Random pentapolymer for treatment of autoimmune diseases
KR20140101730A (en) 2011-10-10 2014-08-20 테바 파마슈티컬 인더스트리즈 리미티드 Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
CA2884267A1 (en) 2012-10-10 2014-04-17 Teva Pharmaceutical Industries Ltd. Biomarkers predictive for clinical response for glatiramer acetate
UY35790A (en) 2013-10-21 2015-05-29 Teva Pharma GENETIC MARKERS THAT PREACH THE RESPONSE TO THE GLATIRAMER ACETATE
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CA3050086A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992002543A1 (en) * 1990-08-01 1992-02-20 Cytel Corporation Novel immunosuppressant peptides
WO1994026774A1 (en) * 1993-05-19 1994-11-24 Cytel Corporation Novel treatments for allergic diseases
WO1995026980A2 (en) * 1994-04-01 1995-10-12 Immulogic Pharmaceutical Corporation Haptenated peptides and uses thereof
WO1995031997A1 (en) * 1994-05-20 1995-11-30 UNITED STATES OF AMERICA, represented by THE SECRETARY OF THE ARMY Model for testing immunogenicity of peptides
WO1996032119A1 (en) * 1995-04-14 1996-10-17 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of gvhd

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4339431A (en) * 1980-12-31 1982-07-13 Colgate-Palmolive Company Anticalculus oral composition
FR2658076B1 (en) * 1990-02-12 1992-06-12 Sanofi Sa COSMETIC COMPOSITION CONTAINING COPOLYMERS OF AMINO ACIDS, USEFUL AS A MOISTURIZING AGENT.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992002543A1 (en) * 1990-08-01 1992-02-20 Cytel Corporation Novel immunosuppressant peptides
WO1994026774A1 (en) * 1993-05-19 1994-11-24 Cytel Corporation Novel treatments for allergic diseases
WO1995026980A2 (en) * 1994-04-01 1995-10-12 Immulogic Pharmaceutical Corporation Haptenated peptides and uses thereof
WO1995031997A1 (en) * 1994-05-20 1995-11-30 UNITED STATES OF AMERICA, represented by THE SECRETARY OF THE ARMY Model for testing immunogenicity of peptides
WO1996032119A1 (en) * 1995-04-14 1996-10-17 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of gvhd

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
AHARONI RINA ET AL: "Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease.", IMMUNOLOGY LETTERS, vol. 58, no. 2, 1997, pages 79 - 87, XP002205821, ISSN: 0165-2478 *
FRIDKIS-HARELI M. ET AL.: "Binding of random copolymers of three aminoacids to class II MHC molecules", INTERNATIONAL IMMUNOLOGY, vol. 11, no. 5, May 1999 (1999-05-01), pages 635 - 641, XP000893153 *
FRIDKIS-HARELI M. ET AL.: "Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility comples molecules on living antigen-presenting cells - specificity and promiscuity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 91, 1994, WASHINGTON US, pages 4872 - 4876, XP000891508 *
LI Q. ET AL.: "Glatiramer acetate blocks the activation of THP-1 cells by interferon-gamma", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 342, 1998, pages 303 - 310, XP000893154 *
SCHLEGEL P G ET AL: "A SYNTHETIC RANDOM BASIC COPOLYMER WITH PROMISCUOUS BINDING TO CLASS II MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULES INHIBITS T-CELLPROLIFERATIVE RESPONSES TO MAJOR AND MINOR HISTOCOMPATIBILITY ANTIGENS IN VITRO AND CONFERS THE CAPACITY TO PREVENT MURINE GRAFT-VERSUS-HOST DISEASE IN VIVO", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 93, no. 10, 14 May 1996 (1996-05-14), pages 5061 - 5066, XP000578029, ISSN: 0027-8424 *
See also references of WO0027417A1 *
SELA M ET AL: "SUPPRESSIVE ACTIVITY OF COP-1 IN EAE AND ITS RELEVANCE TO MULTIPLE SCLEROSIS", BULL. INST. PASTEUR, vol. 88, 1990, pages 303 - 314, XP002926272 *
TEITELBAUM D ET AL: "COPOLYMER 1 FROM THE LABORATORY TO FDA", ISRAEL JOURNAL OF MEDICAL SCIENCES, ISRAEL MEDICAL ASSOCIATION, TEL AVIV, IL, vol. 33, no. 4, April 1997 (1997-04-01), pages 280 - 284, XP002926268, ISSN: 0021-2180 *
TEITELBAUM D ET AL: "CROSS-REACTIONS AND SPECIFICITIES OF MONOCLONAL ANTIBODIES AGAINST MYELIN BASIC PROTEIN AND AGAINST THE SYNTHETIC COPOLYMER1", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 88, November 1991 (1991-11-01), pages 9528 - 9532, XP002949037, ISSN: 0027-8424 *
TEITELBAUM D ET AL: "SUPPRESSION OF EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS BY A SYNTHETIC POLYPEPTIDE", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 1, 1971, pages 242,244,246,248, XP002926270, ISSN: 0014-2980 *
TEITELBAUM D ET AL: "SYNTHETIC COPOLYMER 1 INHIBITS HUMAN T-CELL LINES SPECIFIC FOR MYELIN BASIC PROTEIN", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 89, January 1992 (1992-01-01), pages 137 - 141, XP002924839, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
CA2355400A1 (en) 2000-05-18
EP1128839A1 (en) 2001-09-05
AU775073C (en) 2007-05-03
AU775073B2 (en) 2004-07-15
WO2000027417A1 (en) 2000-05-18
AU1727000A (en) 2000-05-29

Similar Documents

Publication Publication Date Title
EP1128839A4 (en) Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd
IL127545A0 (en) Compositions and methods for administering borrelia DNA
PL343005A1 (en) Pharmaceutical compositions for prolonged peptide release and preparation method
ZA974268B (en) Ethylene copolymers and blend compositions
HUP9900935A3 (en) Antifungic and antibacterial peptide and process for preparation
EP1025165A4 (en) Process and compositions containing polyphenol copolymers
IL138888A0 (en) Pharmaceutical composition and combination preparation for immunosuppressive therapy
HUP0100082A3 (en) Thrombin inhibitor, peptide derivatives, pharmaceutical compositions comprising thereof and their use
IL140742A0 (en) Raloxifene and pharmaceutical composition comprising the same
IL125908A (en) Peptides and pharmaceutical compositions comprising same
SG71754A1 (en) Copolymer and copolymer composition
HUP0000460A3 (en) Imidazopyridazines and pharmaceutical compositions thereof
IL125262A0 (en) Synthetic peptides and pharmaceutical compositions comprising them
IL121329A (en) Pharmaceutical composition for the treatment of cancer comprising somatostatin2 and other peptides
ZA9710934B (en) Compositions and methods for administering pneumococal dna
HUT74745A (en) Pharmaceutical compositions containing p antagonist for treating pruritis, eye- and eyelid-acs and eye-and eyelid dysaesthesia
AU2001291994A1 (en) Dipeptide ligands of the npff receptor for treating pain and hyperalgesia
EP0987942A4 (en) Pharmaceutical composition and methods for using it
GB9606579D0 (en) Pharmaceutical composition and methods for the manufacture thereof
GB9623962D0 (en) Pharmaceutical composition
PL331283A1 (en) Preparation for treating and/or preventing stupefaction
IL116976A0 (en) Synthetic peptides and pharmaceutical compositions comprising them
IL137076A0 (en) Bibapctitide-based pharmaceutical compositions for imaging and treating thrombi
EP0975610A4 (en) Tripeptide and tetrapeptide pharmaceutical compounds
ZA9811105B (en) Cosmetic and pharmaceutical composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010612

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07K 5/00 A, 7C 07K 7/00 B, 7A 61K 38/00 B, 7C 07K 16/00 B, 7G 01N 33/53 B

A4 Supplementary search report drawn up and despatched

Effective date: 20020823

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20050818

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: YEDA RESEARCH AND DEVELOPMEMT CO., LTD.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: YEDA RESEARCH AND DEVELOPMENT CO., LTD.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20100427